Figure 5From: Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial Median MIC for moxifloxacin for Haemophilus influenzae , Streptococcus pneumoniae , Staphylococcus aureus and Pseudomonas aeruginosa. Data are shown for the entire 72 weeks of the study: 48 weeks of intermittent therapy and 24 weeks of follow-up. S, screening visit; R, randomization visit; EOT, end-of-treatment visit; MIC, minimum inhibitory concentration; numbers in the table are of patients with an isolate at a given time point.Back to article page